The Effect of Exercise-Based Interventions on Health-Related Quality of Life of Patients with Hematological Malignancies: A Systematic Review and Meta-Analysis.

: Hematological cancers encompass a collection of heterogeneous conditions. The need for repeated treatments and prolonged hospitalization leads to a decrease in health-related quality of life. This systematic review and meta-analysis evaluate the effect of exercise interventions on functioning scales, global health status, and symptoms in patients with hematological cancers. : PubMed, Web of Science, and Scopus databases were systematically screened, and randomized controlled trials were included. The primary outcome was health-related quality of life assessed through the European Organization for Research and Treatment of Cancer Quality of Life questionnaire. Meta-analysis was performed using a random-effects model and 95% confidence intervals. : A total of 14 trials involving 837 patients with mixed cancer types were included. Most studies evaluated exercise interventions during hospitalization, with aerobic and resistance training at moderate intensity being the most common modalities and adherence rates ranging from 28% to 100%. Exercise programs significantly improved physical (SMD 0.23; 95% CI: 0.06 to 0.40; = 0.008), emotional (SMD 0.19; 95% CI: 0.03 to 0.36; = 0.020) and cognitive functioning (SMD 0.20; 95% CI: 0.02 to 0.37; = 0.026), and global health status (SMD 0.24; 95% CI: 0.03 to 0.46; = 0.027). Significant reductions were observed in fatigue (SMD -0.33; 95% CI: -0.52 to -0.14; = 0.001), pain (SMD -0.34; 95% CI: -0.53 to -0.15; = 0.000), and insomnia (SMD -0.22; 95% CI: -0.41 to -0.03; = 0.024). Heterogeneity was minimal across most domains, suggesting consistent findings. : Exercise interventions are effective in enhancing functioning scales and global health status and reducing symptom burden in patients receiving intensive treatments. Future research is required to explore the long-term effects of exercise and develop tailored programs for specific hematologic malignancies and treatment settings.